Deutsche Bank analyst Justin Bowers raised the firm’s price target on 10x Genomics (TXG) to $14 from $10 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics: Balanced Outlook Amid Growth and Uncertainties
- 10x Genomics price target raised to $15 from $13 at Barclays
- 10x Genomics Reports Strong Q2 2025 Results
- 10x Genomics: Hold Rating Amidst Macroeconomic Challenges and Strategic Moves
- 10x Genomics to acquire Scale Biosciences, terms not disclosed